Gastroenterology

 
Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS
October 30, 2025

One in ten adults report NCGWS, frequently coexisting with IBS, anxiety, or depression, suggesting a central role for the gut-brain axis in pathophysiology.

FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment
October 14, 2025

FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.

FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose
October 14, 2025

Your daily dose of the clinical news you may have missed.

Differential Diagnosis: Distinguishing UACS from Asthma and GERD
October 08, 2025

A family medicine physician details how to differentiate upper airway cough syndrome from asthma and GERD using clinical history and associated symptoms.

FDA Approves Guselkumab as First IL-23 Inhibitor With Fully Subcutaneous Induction Regimen for Ulcerative Colitis
September 22, 2025

FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.

FIT Tests, Direct Mailed, Increase Initiation of CRC Screening in Adults Aged 45 to 49
August 05, 2025

For initiating colorectal cancer screening in average-risk young adults, a default mailed outreach strategy outperformed 3 active choice options in a randomized study.

Fecal Microbiota Transplant Found Noninferior to Antibiotic as Initial Treatment for C. Diff
June 17, 2025

Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.

Real-World Study Confirms Upadacitinib’s Efficacy in Crohn Disease Treatment: Daily Dose
May 29, 2025

Your daily dose of the clinical news you may have missed.

Fecal Microbiota Treatment via Colonoscopy Safe, Effective for Recurrent C. Diff, Study Suggests
May 05, 2025

DDW 2025. Colonoscopic delivery of fecal therapy prevented recurrent C. diff infection in 95% of participants for 8 weeks, with mild GI adverse events reported by

Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients
April 25, 2025

Upadacitinib shows promising real-world effectiveness for managing moderate-to-severe Crohn disease, even in patients with prior treatment exposure.